Related Experiment Video

Updated: Jun 1, 2025

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

16.3K

Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer

Rahat Alam1,2,3, Anna Reva1,2,3, David G Edwards4,5,6

  • 1Icahn School of Medicine, Mount Sinai, New York, New York.

Cancer Discovery
|January 21, 2025
PubMed
Abstract

Insights

Blocking human epidermal growth factor receptor 2 (HER2)-mediated metastasis improves outcomes for breast cancer patients. HER2 is identified as a key biomarker for bone metastasis in HR+/HER2- breast cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis Research

Background:

  • Metastasis remains a primary cause of cancer-related mortality.
  • Strategies to block metastasis progression are urgently needed.
  • Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancer cases.

Purpose of the Study:

  • To investigate the role of HER2 in mediating secondary metastasis.
  • To evaluate the clinical impact of blocking HER2-mediated metastasis.
  • To establish HER2 as a potential biomarker for bone metastasis in HR+/HER2- breast cancer.

Main Methods:

  • The study likely involved preclinical models and patient data analysis.
  • Investigated the mechanisms of HER2-mediated metastasis.
  • Correlated HER2 status with bone metastasis incidence and patient outcomes.

Main Results:

  • Blocking HER2-mediated secondary metastasis was shown to improve clinical outcomes.
  • HER2 was established as a significant biomarker for bone metastasis in the studied patient cohort.
  • This finding is particularly relevant for the large subset of HR+/HER2- breast cancer patients.

Conclusions:

  • Targeting HER2-mediated metastasis offers a promising therapeutic strategy.
  • HER2 serves as a valuable biomarker for predicting bone metastasis risk in HR+/HER2- breast cancer.
  • These findings contribute to developing more effective treatments for breast cancer metastasis.

More Related Videos

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

40.6K
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.2K

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K